Bajaj Healthcare Limited has recently informed exchanges that the company has signed a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European entity. Following its development, this API will be initially supplied in small quantities and utilized by the EU partner to carry out clinical trials for an alternative indication.
In the exchange filing the company also shared, “The trust reposed in our Company by the EU partner for sourcing clinical trial quantities is a testimony of the Company’s development and manufacturing capabilities along with the Good Manufacturing Practices (GMP) compliance at Company’s manufacturing units.”
Based on the results of these trials, supplies will be made at the company’s FDA-approved manufacturing plant in Savli, Vadodara.
